Drug Type Small molecule drug |
Synonyms Abetafen, Modrastane, Modrefen + [6] |
Target |
Mechanism ERβ modulators(Estrogen receptor beta modulators) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (31 Dec 1984), |
Regulation- |
Molecular FormulaC20H27NO3 |
InChIKeyKVJXBPDAXMEYOA-CXANFOAXSA-N |
CAS Registry13647-35-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01180 | Trilostane |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cushing Syndrome | JP | 03 Feb 1986 | |
Hyperaldosteronism | JP | 03 Feb 1986 | |
Prostatic Cancer | US | 31 Dec 1984 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of prostate | Phase 2 | US | 01 Mar 2004 | |
Castration-Resistant Prostatic Cancer | Phase 2 | US | 01 Mar 2004 |
Not Applicable | 714 | vpyzgvqrsh(olislefgww) = dxogimcspj nhcgwmltbq (jajtsmysno ) View more | - | 15 Jul 2004 |